Molecular markers for early detection

Seminars in Oncology

Volumn 37, Issue 3, 2010, Pages 224-242

  Dunn, Barbara K ^a   Wagner, Paul D ^a   Anderson, Darrell ^b   Greenwald, Peter ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Scientific Consulting Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MOLECULAR MARKER; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COLORECTAL CANCER; DIAGNOSTIC IMAGING; DNA METHYLATION; EARLY DIAGNOSIS; ESOPHAGUS CANCER; GENE MUTATION; GENETIC SCREENING; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MALIGNANT TRANSFORMATION; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VALIDITY; CONTACT DERMATITIS; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE;

DERMATITIS, CONTACT; EARLY DETECTION OF CANCER; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956019026     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.05.007     Document Type: Article

References (87)

1. P. Greenwald, and B.K. Dunn Landmarks in the history of cancer epidemiology Cancer Res 69 2009 2151 2162
2. Society of Actuaries. Joint Committee of the Actuarial Society of America and the Association of Life Insurance Medical Directors Blood pressure Report 1-54. New York, NY 1925
3. H.P. Dustan 50th anniversary historical article Hypertension J Am Coll Cardiol 33 1999 595 597
4. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
5. M. Desai, N. Stockbridge, and R. Temple Blood pressure as an example of a biomarker that functions as a surrogate Am Assoc Pharmaceut Sci J 8 2006 E146 E152
6. M.S. Pepe, R. Etzioni, and Z. Feng Phases of biomarker development for early detection of cancer J Natl Cancer Inst 93 2001 1054 1061
7. National Cancer Institute. Division of Cancer Prevention. The Early Detection Research Network: translational research to identify early cancer and cancer risk. Initial report October 2000. 1-44. 2000. National Cancer Institute, Division of Cancer Prevention. 3-4-2010.
8. S. Srivastava, and R. Gopal-Srivastava Biomarkers in cancer screening: a public health perspective J Nutr 132 2002 2471S 2475S
9. Cancer Biomarkers Research Group EDRN Fourth Report: Investing in translational research on biomarkers of early cancer and cancer risk NIH Publication No. 07-6135 2008 National Institutes of Health, National Cancer Institute Bethesda, MD 1 126 http://edrn.nci.nih.gov/docs/progress-reports/edrn- 4th-report-200801.pdf Accessed February 26, 2010
10. G.L. Anderson, M. McIntosh, and L. Wu Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J Natl Cancer Inst 102 2010 26 38
11. C.J. Fabian, and B.F. Kimler Use of biomarkers for breast cancer risk assessment and prevention J Steroid Biochem Mol Biol 106 2007 31 39
12. K.P. Pritzker Cancer biomarkers: easier said than done Clin Chem 48 2002 1147 1150
13. E.S. Leman, R.E. Schoen, and J.L. Weissfeld Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers Cancer Res 67 2007 5600 5605
14. C. Grunau, M.E. Brun, and I. Rivals BAGE hypomethylation, a new epigenetic biomarker for colon cancer detection Cancer Epidemiol Biomarkers Prev 17 2008 1374 1379
15. M.S. Kim, J. Lee, and D. Sidransky DNA methylation markers in colorectal cancer Cancer Metastasis Rev 29 2010 181 206
16. D.A. Ahlquist, D.J. Sargent, and C.L. Loprinzi Stool DNA and occult blood testing for screen detection of colorectal neoplasia Ann Intern Med 149 2008 441 450 W81
17. W.D. Chen, Z.J. Han, and J. Skoletsky Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene J Natl Cancer Inst 97 2005 1124 1132
18. J.A. Marrero, Z. Feng, and Y. Wang Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma Gastroenterology 137 2009 110 118
19. A.S. Lok, R.K. Sterling, and J.E. Everhart Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma Gastroenterology 138 2010 493 502
20. Y. Sun, W. Mi, and J. Cai Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma J Proteome Res 7 2008 3847 3859
21. T. Akagi, T. Ito, and M. Kato Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma Int J Cancer 125 2009 2349 2359
22. G.Y. Locker, S. Hamilton, and J. Harris ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 2006 5313 5327
23. S.T. Lott, N. Chen, and D.S. Chandler DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer PLoS Med 6 2009 e1000068
24. I. Irminger-Finger BARD1, a possible biomarker for breast and ovarian cancer Gynecol Oncol 117 2010 211 215
25. W. Wang, and S. Srivastava Strategic approach to validating methylated genes as biomarkers for breast cancer Cancer Prev Res 3 2010 16 24
26. M.J. Fackler, M. McVeigh, and J. Mehrotra Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer Cancer Res 64 2004 4442 4452
27. C.A. Shah, K.A. Lowe, and P. Paley Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125 Cancer Epidemiol Biomarkers Prev 18 2009 1365 1372
28. S.N. Stacey, P. Sulem, and O.T. Johannsson The BARD1 Cys557Ser variant and breast cancer risk in Iceland PLoS Med 3 2006 e217
29. T.R. Rebbeck, N. Mitra, and S.M. Domchek Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers Cancer Res 69 2009 5801 5810
30. C.M. Martin, K. Astbury, L. McEvoy, S. O'Toole, O. Sheils, and J.J. O'Leary Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy Methods Mol Biol 511 2009 333 359
31. Y. Lotan, and C.G. Roehrborn Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 61 2003 109 118
32. H.S. Park, W.S. Park, and J. Bondaruk Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection J Natl Cancer Inst 100 2008 1401 1411
33. J. Qiu, G. Choi, and L. Li Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera J Clin Oncol 26 2008 5060 5066
34. S.A. Belinsky, K.C. Liechty, and F.D. Gentry Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort Cancer Res 66 2006 3338 3344
35. W. Han, T. Wang, A.A. Reilly, S.M. Keller, and S.D. Spivack Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients Respir Res 10 2009 86
36. H. Tezval, A.S. Merseburger, I. Matuschek, S. Machtens, M.A. Kuczyk, and J. Serth RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma BMC Urol 8 2008 12
37. I. Martinez, J. Wang, K.F. Hobson, R.L. Ferris, and S.A. Khan Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas Eur J Cancer 43 2007 415 432
38. M.F. Calmon, R.V. Rodrigues, and C.M. Kaneto Epigenetic silencing of CRABP2 and MX1 in head and neck tumors Neoplasia 11 2009 1329 1339
39. M. Hussain, B. Goldman, and C. Tangen Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 J Clin Oncol 27 2009 2450 2456
40. G. Sardana, B. Dowell, and E.P. Diamandis Emerging biomarkers for the diagnosis and prognosis of prostate cancer Clin Chem 54 2008 1951 1960
41. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
42. R.S. Mani, S.A. Tomlins, and K. Callahan Induced chromosomal proximity and gene fusions in prostate cancer Science 326 2009 1230
43. J.M. Mosquera, R. Mehra, and M.M. Regan Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States Clin Cancer Res 15 2009 4706 4711
44. B. Laxman, D.S. Morris, and J. Yu A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res 68 2008 645 649
45. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
46. M. Ruault, P. van der Bruggen, M.E. Brun, S. Boyle, G. Roizes, and S.A. De New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile Eur J Hum Genet 10 2002 833 840
47. C. Grunau, C. Sanchez, and M. Ehrlich Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer Genes Chromosomes Cancer 43 2005 11 24
48. S.H. Itzkowitz, L. Jandorf, and R. Brand Improved fecal DNA test for colorectal cancer screening Clin Gastroenterol Hepatol 5 2007 111 117
49. A.J. Gomes, H.K. Roy, and V. Turzhitsky Rectal mucosal microvascular blood supply increase is associated with colonic neoplasia Clin Cancer Res 15 2009 3110 3117
50. K.S. Looi, E.S. Nakayasu, R.A. Diaz, E.M. Tan, I.C. Almeida, and J.Y. Zhang Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma J Proteome Res 7 2008 4004 4012
51. A. Mehta, and T.M. Block Fucosylated glycoproteins as markers of liver disease Dis Markers 25 2008 259 265
52. R. Goldman, H.W. Ressom, and M. Abdel-Hamid Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum Carcinogenesis 28 2007 2149 2153
53. R. Goldman, H.W. Ressom, and R.S. Varghese Detection of hepatocellular carcinoma using glycomic analysis Clin Cancer Res 15 2009 1808 1813
54. Z. Jin, Y. Cheng, and W. Gu A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus Cancer Res 69 2009 4112 4115
55. P.C. Galipeau, X. Li, and P.L. Blount NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma PLoS Med 4 2007 e67
56. J.E. Kim, K.T. Lee, J.K. Lee, S.W. Paik, J.C. Rhee, and K.W. Choi Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population J Gastroenterol Hepatol 19 2004 182 186
57. V.M. Faca, K.S. Song, and H. Wang A mouse to human search for plasma proteome changes associated with pancreatic tumor development PLoS Med 5 2008 e123
58. H.J. Zeh, S. Winikoff, and D.P. Landsittel Multianalyte profiling of serum cytokines for detection of pancreatic cancer Cancer Biomark 1 2005 259 269
59. H.H. Wandall, O. Blixt, and M.A. Tarp Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes Cancer Res 70 2010 1306 1313
60. T. Yue, I.J. Goldstein, M.A. Hollingsworth, K. Kaul, R.E. Brand, and B.B. Haab The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays Mol Cell Proteomics 8 2009 1697 1707
61. C.J. Fabian, B.F. Kimler, M.S. Mayo, and S.A. Khan Breast-tissue sampling for risk assessment and prevention Endocr Relat Cancer 12 2005 185 213
62. G.J. Kelloff, S.M. Lippman, and A.J. Dannenberg Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancera plan to move forward Clin Cancer Res 12 2006 3661 3697
63. U. Menon, A. Gentry-Maharaj, and R. Hallett Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Lancet Oncol 10 2009 327 340
64. Agency for Healthcare Research and Quality Evaluation of cervical cytology Summary, evidence report/technology assessment: number 5 January 1999 Agency for Health Care Policy and Research, Rockville, MD Rockville, MD http://www.ahrq.gov/clinic/epcsums/cervsumm.htm Accessed February 26, 2010
65. M. Stephenson, and C. Doughty Performance of commercially available HPV tests NZHTA Technical Brief 6 2007 1 64
66. A. Balasubramanian, J. Hughes, and C. Mao Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer Cancer Epidemiol Biomarkers Prev 18 2009 3008 3017
67. F.M. Brown Urine cytology It is still the gold standard for screening? Urol Clin North Am 27 2000 25 37
68. US Food and Drug Administration Premarket approval of Matritech Inc Matritech NMP22 test kit http://www.accessdata.fda.gov/cdrh-docs/pdf/p940035. pdf Accessed March 16, 2010
69. E. Chiong, K.E. Gaston, and H.B. Grossman Urinary markers in screening patients with hematuria World J Urol 26 2008 25 30
70. C. Zippe, L. Pandrangi, and A. Agarwal NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer J Urol 161 1999 62 65
71. B.J. Schlomer, R. Ho, A. Sagalowsky, R. Ashfaq, and Y. Lotan Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder J Urol 183 2010 62 67
72. G. Steiner, M.P. Schoenberg, J.F. Linn, L. Mao, and D. Sidransky Detection of bladder cancer recurrence by microsatellite analysis of urine Nat Med 3 1997 621 624
73. D.W. Lin Beyond PSA: utility of novel tumor markers in the setting of elevated PSA Urol Oncol 27 2009 315 321
74. D.A. Troyer, M.S. Lucia, and A.P. de Bruine Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies Cancer Epidemiol Biomarkers Prev 18 2009 2717 2722
75. A.Y. Liu, M.P. Roudier, and L.D. True Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile Am J Pathol 165 2004 1543 1556
76. Canary Foundation Prostate Active Surveillance Study (PASS) 2010 Canary Foundation Stanford, CA http://www.canaryfoundation.org/prostate-clinical- studies.cfm Accessed March 10, 2010
77. S. Roemeling, M.J. Roobol, and S.H. de Vries Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome Eur Urol 51 2007 1244 1250
78. O. Topaloglu, M.O. Hoque, and Y. Tokumaru Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer Clin Cancer Res 10 2004 2284 2288
79. I. Horvath, Z. Lazar, N. Gyulai, M. Kollai, and G. Losonczy Exhaled biomarkers in lung cancer Eur Respir J 34 2009 261 275
80. R.R. Drake, L.H. Cazare, O.J. Semmes, and J.T. Wadsworth Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers Expert Rev Mol Diagn 5 2005 93 100
81. S.S. Chang, and J. Califano Current status of biomarkers in head and neck cancer J Surg Oncol 97 2008 640 643
82. N. Ramachandran, J.V. Raphael, and E. Hainsworth Next-generation high-density self-assembling functional protein arrays Nat Methods 5 2008 535 538
83. K.S. Anderson, N. Ramachandran, and J. Wong Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer J Proteome Res 7 2008 1490 1499
84. F. Harinck, J.W. Poley, and I. Kluijt Comparative yield of endosonography and magnetic resonance imaging in individuals at high-risk for pancreatic cancer Gastroenterology 136 2009 A147
85. P. Alfonso, A. Nunez, J. Madoz-Gurpide, L. Lombardia, L. Sanchez, and J.I. Casal Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis Proteomics 5 2005 2602 2611
86. T. Qi, J. Han, Y. Cui, M. Zong, X. Liu, and B. Zhu Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas J Clin Pathol 61 2008 49 58
87. B. Sitek, B. Sipos, and I. Alkatout Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation J Proteome Res 8 2009 1647 1656